We validated these findings by studying a small clinical cohort of two pediatric patients bearing pathogenic MEF2C point mutations resulting in MEF2C haploinsufficiency syndrome (MCHS), a recently characterized neurodevelopmental syndrome with no known associated immune defects.6 Here, MEF2C is linked to Down syndrome.